Please login to the form below

Not currently logged in
Email:
Password:

balugrastim

This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.

EMA backs 15 new medicines for use in EU

EMA backs 15 new medicines for use in EU

tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    Teva withdraws US filing for cancer biologic. FDA requests more data for balugrastim. ... Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim.

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics